OSI, Genentech, Pfizer and Teva Reach Settlement Agreement in Tarceva® Patent Case

Tokyo, March 16, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that OSI Pharmaceuticals, Inc. (a subsidiary of Astellas), Genentech, Inc. (a member of the Roche Group - SIX: RO, ROG; OTCQX: RHHBY), and Pfizer Inc. (NYSE:PFE) have reached an agreement with Teva Pharmaceuticals USA, Inc. (“Teva”) to settle the pending U.S. litigation filed March 19, 2009 against Teva with regard to US Patent Nos. 6,900,221, RE 41,065 and 7,087,613 for Tarceva® (erlotinib hydrochloride) tablets, through which the case against Teva will be terminated by a Consent Order of Dismissal. The terms of the settlement are not disclosed. ### OSI, Genentech, Pfizer and Teva Reach Settlement Agreement in Tarceva® Patent Case (pdf 27KB) Contact the Media Relations team Communications & Investor Relations Main phone line for Media: ＋81-3244-3201 Business hours (JST) From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm (closed on Saturdays, Sundays, national holidays and company holidays)

The release as fetched from its publisher. astellas.com ↗